JP2013542195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542195A5 JP2013542195A5 JP2013530396A JP2013530396A JP2013542195A5 JP 2013542195 A5 JP2013542195 A5 JP 2013542195A5 JP 2013530396 A JP2013530396 A JP 2013530396A JP 2013530396 A JP2013530396 A JP 2013530396A JP 2013542195 A5 JP2013542195 A5 JP 2013542195A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- composition according
- present
- subject
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 49
- 230000001225 therapeutic effect Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 12
- 229930182817 methionine Natural products 0.000 claims description 12
- 206010003694 Atrophy Diseases 0.000 claims description 11
- 230000037444 atrophy Effects 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002661 proton therapy Methods 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims description 3
- 230000007413 intestinal health Effects 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 238000012084 abdominal surgery Methods 0.000 claims description 2
- 150000008209 arabinosides Chemical class 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38631710P | 2010-09-24 | 2010-09-24 | |
| US61/386,317 | 2010-09-24 | ||
| US201161431629P | 2011-01-11 | 2011-01-11 | |
| US61/431,629 | 2011-01-11 | ||
| PCT/US2011/053265 WO2012040707A2 (en) | 2010-09-24 | 2011-09-26 | Materials and methods for improving gastrointestinal function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016167829A Division JP6425356B2 (ja) | 2010-09-24 | 2016-08-30 | 胃腸機能を改善するための材料および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542195A JP2013542195A (ja) | 2013-11-21 |
| JP2013542195A5 true JP2013542195A5 (enExample) | 2014-12-04 |
| JP6000253B2 JP6000253B2 (ja) | 2016-09-28 |
Family
ID=45871248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530396A Active JP6000253B2 (ja) | 2010-09-24 | 2011-09-26 | 胃腸機能を改善するための材料および方法 |
| JP2016167829A Active JP6425356B2 (ja) | 2010-09-24 | 2016-08-30 | 胃腸機能を改善するための材料および方法 |
| JP2018187236A Active JP6698777B2 (ja) | 2010-09-24 | 2018-10-02 | 胃腸機能を改善するための材料および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016167829A Active JP6425356B2 (ja) | 2010-09-24 | 2016-08-30 | 胃腸機能を改善するための材料および方法 |
| JP2018187236A Active JP6698777B2 (ja) | 2010-09-24 | 2018-10-02 | 胃腸機能を改善するための材料および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US8993522B2 (enExample) |
| EP (5) | EP2624825B1 (enExample) |
| JP (3) | JP6000253B2 (enExample) |
| KR (4) | KR102069790B1 (enExample) |
| CN (2) | CN103153298B (enExample) |
| AP (1) | AP2013006826A0 (enExample) |
| AU (2) | AU2011305124B2 (enExample) |
| BR (1) | BR112013006044B1 (enExample) |
| CA (1) | CA2809489C (enExample) |
| EA (1) | EA030970B8 (enExample) |
| ES (2) | ES2639888T3 (enExample) |
| IL (1) | IL277166B (enExample) |
| MX (2) | MX2013003282A (enExample) |
| NZ (1) | NZ607189A (enExample) |
| PH (1) | PH12013500441A1 (enExample) |
| SG (1) | SG188293A1 (enExample) |
| WO (1) | WO2012040707A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6000253B2 (ja) * | 2010-09-24 | 2016-09-28 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 胃腸機能を改善するための材料および方法 |
| JP2014508580A (ja) * | 2011-01-19 | 2014-04-10 | フラクティル ラボラトリーズ インコーポレイテッド | 組織の治療のためのデバイスおよび方法 |
| MX368543B (es) * | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| WO2014164736A1 (en) * | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| CN110237447B (zh) | 2013-09-27 | 2021-11-02 | 梅维昂医疗系统股份有限公司 | 粒子治疗系统 |
| US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
| US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
| US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
| WO2016085735A1 (en) | 2014-11-24 | 2016-06-02 | Entrinsic Health Solutions, Llc | Amino acid compositions for the treatment of symptoms of disease |
| US20180038873A1 (en) * | 2015-02-05 | 2018-02-08 | University Of Florida Research Foundation, Inc. | Use of nhe3 as a biomarker for radiation biodosimetry |
| US20160339086A1 (en) * | 2015-05-19 | 2016-11-24 | Suzy Cohen | Compositions and methods for treating thyroid disease |
| US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
| CN105685973B (zh) * | 2016-02-04 | 2018-08-24 | 中山大学附属第六医院 | 一种肠内营养剂 |
| US10702590B2 (en) | 2016-04-12 | 2020-07-07 | Script Essentials, Llc | Compositions and methods for treating thyroid disease |
| JP7059245B2 (ja) | 2016-07-08 | 2022-04-25 | メビオン・メディカル・システムズ・インコーポレーテッド | 治療計画の決定 |
| EP3494968A4 (en) * | 2016-08-05 | 2020-04-15 | The University Of Tokyo | COMPOSITION FOR USE IN TREATING T-CELL LEUKEMIA / LYMPHOMA IN ADULTS AND METHOD FOR THE PRODUCTION THEREOF |
| US11576884B2 (en) | 2016-10-04 | 2023-02-14 | University Of Florida Research Foundation, Inc. | Amino acid compositions and uses thereof |
| US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
| EP3645111B1 (en) | 2017-06-30 | 2025-04-23 | Mevion Medical Systems, Inc. | Configurable collimator controlled using linear motors |
| WO2019070750A1 (en) | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation , Incorporated | MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH |
| WO2019070753A1 (en) * | 2017-10-02 | 2019-04-11 | University Of Florida Research Foundation, Incorporated | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA |
| KR20200139776A (ko) * | 2018-04-04 | 2020-12-14 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 피부 치료용 조성물 |
| CN109601761A (zh) * | 2018-11-01 | 2019-04-12 | 山东大学 | 一种大菱鲆肠炎病的营养性修复剂 |
| JP7311620B2 (ja) | 2019-03-08 | 2023-07-19 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのコリメータおよびエネルギーデグレーダ |
| EP3958855A4 (en) * | 2019-04-26 | 2023-01-18 | Increvet, Inc. | METHODS FOR REDUCING WEIGHT LOSS OR INCREASING WEIGHT OF A FELINE IN NEED |
| RU2699222C1 (ru) * | 2019-04-29 | 2019-09-04 | Алексей Владимирович Воронов | Солевой электролитный раствор для проведения энтеральных инфузий |
| CA3143318C (en) * | 2019-06-14 | 2024-06-18 | Cj Cheiljedang Corporation | Composition for preventing, treating, or improving gastrointestinal diseases comprising strain of genus corynebacterium and culture thereof |
| EP4058044A4 (en) * | 2019-11-11 | 2023-05-17 | Ohio State Innovation Foundation | TREATMENT OF INFLAMMATORY BOWEL DISEASE AND RADIATION INDUCED BOWEL DAMAGE |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| MX2022015155A (es) * | 2020-06-02 | 2023-01-11 | Univ Florida | Formulaciones y metodos para tratar la diarrea. |
| IL299488A (en) | 2020-07-02 | 2023-02-01 | Univ Florida | Preparations for promoting hydration and methods of using them |
| IT202200013354A1 (it) * | 2022-06-23 | 2023-12-23 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nella prevenzione e/o nel trattamento di malattie intestinali |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1285491C (en) * | 1985-09-12 | 1991-07-02 | Robert J. Smith | Method of treating catabolic dysfunction |
| SE8601828D0 (sv) * | 1986-04-21 | 1986-04-21 | Novo Industri As | Enteral diet product and agent for production thereof |
| US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
| US5290538A (en) | 1988-12-22 | 1994-03-01 | Skrezek Christian | Nephro protective infusion solutions |
| AU6130594A (en) | 1991-03-05 | 1994-08-15 | Miris Medical Corporation | Method and device for correcting the drift offset of a pressure sensor of a flowmeter |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| NZ248605A (en) | 1993-05-28 | 1994-12-22 | Abbott Lab | Enteral nutritional product comprising protein and fat |
| US5514656A (en) | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy |
| JP3177918B2 (ja) * | 1993-06-24 | 2001-06-18 | 日本電信電話株式会社 | パケット交換機のルーチング装置 |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| JPH07330583A (ja) * | 1994-06-03 | 1995-12-19 | Terumo Corp | 遊離型グルタミン酸を含有する液状製剤 |
| JPH0873351A (ja) * | 1994-06-30 | 1996-03-19 | Ajinomoto Co Inc | 炎症性腸疾患用栄養組成物 |
| EP0689835A3 (en) | 1994-06-30 | 1996-04-17 | Ajinomoto Kk | Composition containing an amino acid mixture and at least one N-3 fatty acid |
| JP4011638B2 (ja) * | 1994-12-27 | 2007-11-21 | イーエヌ大塚製薬株式会社 | 経口経腸栄養組成物 |
| ATE191615T1 (de) | 1995-02-23 | 2000-04-15 | Novartis Nutrition Ag | Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| EP0833670B1 (en) | 1995-06-14 | 2003-09-03 | Baylor College Of Medicine | Vaccine against rotavirus infection comprising peptides of viral enterotoxin nsp4 |
| US6673355B1 (en) | 1995-06-14 | 2004-01-06 | Baylor College Of Medicine | Rotavirus enterotoxin NSP4 and methods of using same |
| US5821217A (en) * | 1995-10-27 | 1998-10-13 | Beth Israel Deaconess Medical Center, Inc. | Enteral formulation: low in fat and containing protein hydrolysates |
| WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| MXPA01002875A (es) | 1998-11-13 | 2002-04-08 | Los Angeles Childrens Hospital | Metodos para facilitar el crecimiento vascular. |
| NZ512383A (en) | 1998-12-22 | 2003-05-30 | Univ North Carolina | Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| US6956023B1 (en) * | 2001-04-19 | 2005-10-18 | University Of Florida | Materials and methods for providing nutrition to neonates |
| JP4255656B2 (ja) | 2001-09-17 | 2009-04-15 | 株式会社メニコン | 眼科用液剤及びコンタクトレンズ用液剤 |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20030143293A1 (en) | 2002-01-31 | 2003-07-31 | Sergei Shushunov | Compositions and methods for treating diarrhea |
| JP2004123642A (ja) | 2002-10-04 | 2004-04-22 | Shimizu Pharmaceutical Co Ltd | 電解質組成物 |
| DK175877B1 (da) | 2002-11-11 | 2005-05-09 | Pharmalett As | Præparater til anvendelse som terapeutisk middel |
| US20040213838A1 (en) | 2003-04-24 | 2004-10-28 | Mazer Terrence B. | Medical food tablets containing free amino acids |
| US20050100637A1 (en) | 2003-11-12 | 2005-05-12 | Robert Murray | Carbohydrate and electrolyte replacement composition |
| JPWO2006049286A1 (ja) | 2004-11-02 | 2008-05-29 | 味の素株式会社 | アレルギー性疾患予防・治療剤 |
| US20070010459A1 (en) | 2005-01-14 | 2007-01-11 | Ying Liu | Application of asiatic acid and its derivatives to treat pulmonary fibrosis |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| JP4811576B2 (ja) | 2005-03-31 | 2011-11-09 | 味の素株式会社 | 水分電解質補給飲料 |
| WO2007004613A1 (ja) | 2005-07-01 | 2007-01-11 | Ajinomoto Co., Inc. | 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤 |
| US7595079B2 (en) | 2005-07-08 | 2009-09-29 | Bomac Vets Plus, Inc. | Nutritional conjunctive support therapy for recovery in animals following stress or illness |
| JP4512013B2 (ja) | 2005-09-07 | 2010-07-28 | 和光堂株式会社 | 液体飲料組成物及びその製造方法 |
| US20070202058A1 (en) | 2006-02-27 | 2007-08-30 | Calwood Nutritionals, Inc. | Compositions for treating gastric reflux |
| CN100522183C (zh) | 2006-03-02 | 2009-08-05 | 上海交通大学 | 治疗咳喘病的地龙酸性部位药及其制备方法 |
| EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| DE102006018293A1 (de) | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| WO2007133642A1 (en) * | 2006-05-11 | 2007-11-22 | Garcia Ramon D | Sport drink containing amino acids and carbohydrates |
| EP2037765A1 (en) | 2006-05-12 | 2009-03-25 | The Coca-Cola Company | Beverage preservatives |
| JP5100033B2 (ja) | 2006-05-16 | 2012-12-19 | 大塚製薬株式会社 | 消化管及び腎臓の萎縮抑制剤 |
| GB0612671D0 (en) * | 2006-06-27 | 2006-08-09 | Shs Int Ltd | Nutritional formulation |
| US8691213B2 (en) | 2006-08-04 | 2014-04-08 | SHS International | Protein free formula |
| BRPI0814745A2 (pt) | 2007-08-03 | 2014-10-07 | Aminotech As | Composição de produto. |
| TWI478709B (zh) | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| US20090318556A1 (en) | 2008-05-15 | 2009-12-24 | Idle Jeffrey R | Biomarkers for detecting radiation exposure: methods and uses thereof |
| JP5576097B2 (ja) | 2009-11-17 | 2014-08-20 | 大塚製薬株式会社 | 気道抵抗改善剤 |
| IT1396935B1 (it) | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
| CN101779750A (zh) * | 2010-03-24 | 2010-07-21 | 舒世洪 | 一种乳猪教槽料及制备方法 |
| WO2011127056A2 (en) | 2010-04-05 | 2011-10-13 | The Uab Research Foundation | Biomarkers for assessing exposure to ionizing radiation and absorbed dose |
| WO2012020357A1 (en) | 2010-08-09 | 2012-02-16 | Advinus Therapeutics Ltd. | Acetamide compounds, their process and pharmaceutical application |
| JP6000253B2 (ja) | 2010-09-24 | 2016-09-28 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 胃腸機能を改善するための材料および方法 |
| US20120321729A1 (en) | 2011-06-15 | 2012-12-20 | Ven Subbiah | Nutritional formula for managing chronic obstructive pulmonary disease (copd) and lung health |
| US8557301B2 (en) | 2011-07-01 | 2013-10-15 | Drip Drop, Inc. | Oral rehydration composition |
| MX368543B (es) | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| US10086007B2 (en) | 2012-04-05 | 2018-10-02 | University Of Florida Research Foundation, Incorporated | Materials and methods for treatment of cystic fibrosis and for induction of ion secretion |
| WO2014164736A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| WO2017118984A1 (en) | 2016-01-06 | 2017-07-13 | Parasonic Ltd. | Device and method for damaging parasites using ultrasonic reflection |
| US11576884B2 (en) | 2016-10-04 | 2023-02-14 | University Of Florida Research Foundation, Inc. | Amino acid compositions and uses thereof |
-
2011
- 2011-09-26 JP JP2013530396A patent/JP6000253B2/ja active Active
- 2011-09-26 ES ES11827720.1T patent/ES2639888T3/es active Active
- 2011-09-26 KR KR1020187035048A patent/KR102069790B1/ko active Active
- 2011-09-26 EP EP11827720.1A patent/EP2624825B1/en active Active
- 2011-09-26 AP AP2013006826A patent/AP2013006826A0/xx unknown
- 2011-09-26 SG SG2013013883A patent/SG188293A1/en unknown
- 2011-09-26 CA CA2809489A patent/CA2809489C/en active Active
- 2011-09-26 WO PCT/US2011/053265 patent/WO2012040707A2/en not_active Ceased
- 2011-09-26 MX MX2013003282A patent/MX2013003282A/es unknown
- 2011-09-26 BR BR112013006044-1A patent/BR112013006044B1/pt active IP Right Grant
- 2011-09-26 EA EA201300323A patent/EA030970B8/ru not_active IP Right Cessation
- 2011-09-26 CN CN201180045566.0A patent/CN103153298B/zh active Active
- 2011-09-26 EP EP24162436.0A patent/EP4406557A3/en active Pending
- 2011-09-26 CN CN201510691368.1A patent/CN105663106A/zh active Pending
- 2011-09-26 KR KR1020207001701A patent/KR102205124B1/ko active Active
- 2011-09-26 AU AU2011305124A patent/AU2011305124B2/en active Active
- 2011-09-26 US US13/245,430 patent/US8993522B2/en active Active
- 2011-09-26 EP EP16201706.5A patent/EP3173079B1/en active Active
- 2011-09-26 MX MX2015017157A patent/MX350541B/es unknown
- 2011-09-26 EP EP21159441.1A patent/EP3970715A1/en active Pending
- 2011-09-26 PH PH1/2013/500441A patent/PH12013500441A1/en unknown
- 2011-09-26 EP EP18213818.0A patent/EP3494969B1/en active Active
- 2011-09-26 ES ES16201706T patent/ES2805535T3/es active Active
- 2011-09-26 KR KR1020137007214A patent/KR101758424B1/ko active Active
- 2011-09-26 KR KR1020177019051A patent/KR20170084354A/ko not_active Ceased
- 2011-09-26 NZ NZ60718911A patent/NZ607189A/en not_active IP Right Cessation
-
2015
- 2015-03-12 US US14/656,255 patent/US10322109B2/en active Active
- 2015-07-30 AU AU2015207919A patent/AU2015207919B2/en active Active
-
2016
- 2016-08-30 JP JP2016167829A patent/JP6425356B2/ja active Active
-
2018
- 2018-10-02 JP JP2018187236A patent/JP6698777B2/ja active Active
- 2018-10-18 US US16/164,399 patent/US20190046504A1/en not_active Abandoned
-
2019
- 2019-06-14 US US16/441,062 patent/US10940137B2/en active Active
-
2020
- 2020-09-06 IL IL277166A patent/IL277166B/en active IP Right Grant
-
2021
- 2021-01-29 US US17/161,811 patent/US11752132B2/en active Active
-
2023
- 2023-08-01 US US18/363,448 patent/US12239633B2/en active Active
-
2025
- 2025-01-16 US US19/023,953 patent/US20250248972A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542195A5 (enExample) | ||
| ES2580127T3 (es) | Procedimiento de tratamiento de la nefropatía crónica | |
| ES2962302T3 (es) | Tratamiento de la colestasis intrahepática y hepatopatías relacionadas | |
| KR102093872B1 (ko) | 지방제거용 주사제 조성물 및 이의 제조방법 | |
| TW201625271A (zh) | 含有槲皮素配糖體之筋萎縮抑制劑 | |
| Hu et al. | Pyruvate-enriched oral rehydration solution improved intestinal absorption of water and sodium during enteral resuscitation in burns | |
| CN102578588B (zh) | 一种对运动和性机能有促进作用的组合物 | |
| AU2017279592A1 (en) | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies | |
| RU2010129825A (ru) | Материалы и способы для лечения патологической пролиферации глазных сосудов | |
| TWI269656B (en) | Therapeutical composition for hepatitis C | |
| JP2020500864A5 (enExample) | ||
| KR20090033871A (ko) | 비페프루녹스 및 ｌ-ｄｏｐａ를 포함하는 병용 제제 | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| CN108186631B (zh) | 一种药物组合物及其制备方法和用途 | |
| CN105012292A (zh) | 一种药物组合物及其用途 | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| EP2522350A1 (de) | Verwendung der Wirkstoffkombination aus einem 1-Diethylaminoethyl-3-Chinoxalin-2-on Derivat und einem Oxysterol zur Durchbrechung von Resistenzen bei der Behandlung von Krebs und zur Erhöhung der Immunleistungsfähigkeit bei Krebs, bakteriellen und viralen Erkrankungen, Autoimmunerkrankungen, erhöhter Stress- und Umweltbelastung | |
| EP4142692A2 (en) | Superoxide dismutase compositions and methods | |
| CN104688762A (zh) | 一种含12种维生素供静脉注射使用的药物组合物 | |
| RU2539377C2 (ru) | Способ лечения атеросклероза, основанный на антицитокиновом действии | |
| CN107737108A (zh) | 一种治疗心肌梗死后心室重塑的口服药物组合物 | |
| CN104161764A (zh) | 含有苦参素和甘草酸的药物组合物制备治疗银屑病的应用 | |
| RU2458537C1 (ru) | Биологически активная добавка к пище для профилактики эректильной дисфункции у мужчин | |
| CN102552633B (zh) | 一种药物组合物 | |
| RU2484841C1 (ru) | Способ профилактики атеросклероза, основанный на подавлении атерогенной модификации липопротеидов |